Navigation Links
Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%

nd penalties of $38.1 million.

At December 31, 2007 net deferred tax liabilities of $56.7 million (December 31, 2006: net deferred tax asset of $261.0 million) were recognized. Shire has moved from a net deferred tax asset to a net deferred tax liability position primarily because of the recognition of a deferred tax liability of $394.8 million at acquisition in respect of intangible assets acquired with New River, offset by deferred tax asset of $46.7 million relating to New River's net operating loss carry forwards.

Equity in earnings of equity method investees

Net earnings of equity method investees of $1.8 million were recorded for the year to December 31, 2007 (2006: $5.7 million). This comprised earnings of $6.5 million from the 50% share of the anti-viral commercialization partnership with GSK in Canada (2006: $6.2 million), offset by losses of $4.7 million being the Company's share of losses in the GeneChem, AgeChem and EGS Healthcare Funds (2006: losses of $0.5 million).

FAS123R compensation cost

The total FAS123R charge for the year was $75.2 million (2006: $43.0 million). Excluding a catch-up charge of $29.2 million there was a 7% increase in the FAS123R charge over 2006.

The catch up charge relates to options issued by Shire in 2005 under the 2000 Executive Scheme. This charge arises as a result of the strong growth in revenue and profits which the Company has generated in Q4 2007. This growth has in turn caused the Company to revise its original assumptions on which the FAS123R charge was based.

Financial Information

Unaudited US GAAP results for the year to December 31, 2007

Consolidated Balance Sheets

December 31,

December 31,

2007 2006


SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire plc: Correction Re Website
2. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
3. Shire Engages Palio
4. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
5. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
6. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire plc: Board Changes
9. David Mott Appointed Non Executive Director at Shire
10. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
11. Shire Divests Non-Core Product Portfolio to Almirall
Post Your Comments:
(Date:9/30/2014)... Basel, Switzerland (PRWEB) September 30, 2014 ... advanced software solutions for drug discovery and ... the FUNGITECT consortium has chosen Genedata Selector ... next-generation sequencing (NGS) data. FUNGITECT is a ... of invasive fungal diseases via individualized anti-fungal ...
(Date:9/30/2014)... Md., Sept. 30, 2014 BioHealth Innovation, ... commercializing market-relevant biohealth innovations and increasing access to early-stage ... today that venture capitalist, Tania Fernandez , Ph.D., ... Dr. Fernandez will be a member of the management ... provide up to $50 million in seed and early-stage ...
(Date:9/30/2014)... Sept. 30, 2014 The overall research ... (NGS) sequencing trends and use. Most researchers outsource ... expected to increase within the next 12 months. ... criteria for purchasing sequencing instruments. Disease-related research is ... of RNA-Seq continues to surge, with half of ...
(Date:9/30/2014)... MA (PRWEB) September 30, 2014 ... (UC) and collaboration company is dedicated to supporting ... connectivity needs. Julie Power, a carrier ... to ensure collaboration solutions stays connected and productive ... to the increased movement of businesses to cloud ...
Breaking Biology Technology:FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3Seasoned Life Sciences Venture Capitalist Tania Fernandez Joins BHI to Help Manage New BioHealth Gap Fund 2Global Next-generation Sequencing Trends 2SoundConnect Expands Carrier Services Division 2
... in the lower half of states in federal contracting ... researchers and companies land more federal security contracts. , ... a grant from the U.S. Small Business Administration ... classified research. , ,What we're trying to do is ...
... Madison, Wis. - Mirus Bio Corp. ... $900,000 to extend its microRNA detection technology for clinical ... life-science company engaged in gene therapy and the study ... National Institute of General Medical Sciences . It ...
... dependence on transportation infrastructure between Illinois and Wisconsin. ... and existing developments was highlighted. Building a true ... great supporting infrastructure, but I was surprised at ... Zielonka, a CPA, commented that the Chicago-Milwaukee connection ...
Cached Biology Technology:Research consortium aims to bring security and defense contracts to Wisconsin 2Mega-Metro Center may go beyond Chicago and Wisconsin 2Mega-Metro Center may go beyond Chicago and Wisconsin 3Mega-Metro Center may go beyond Chicago and Wisconsin 4Mega-Metro Center may go beyond Chicago and Wisconsin 5
(Date:9/30/2014)... almost any aquatic environment on Earth, but when the ... pushed to the limit. The amount of time needed ... how different species cope in the future, reveals a ... published in the scientific journal Proceedings of the ... thanks to increasing levels of greenhouse gases in the ...
(Date:9/30/2014)... in urban and farm runoff in Hawaii is causing ... , The study, published Tuesday in the peer-reviewed ... the runoff ends up in algae that the turtles ... eyes, flippers and internal organs. , Scientists at Duke ... and Atmospheric Administration (NOAA) conducted the study to better ...
(Date:9/30/2014)... (LMU) in Munich report that a new class ... to chemotherapeutic drugs. They have also pinpointed the ... for anti-tumor agents. , Researchers led by ... of the Technische Universitt Mnchen have identified a ... weapon in the fight against malignant tumors. The ...
Breaking Biology News(10 mins):Shape up quickly -- applies to fish, too! 2Pollution linked to lethal sea turtle tumors 2Pollution linked to lethal sea turtle tumors 3Cancer therapy: Driving cancer cells to suicide 2
... has found that protein and not sugar activates the ... The research, published in the 17 November issue ... for understanding obesity and sleep disorders. Wakefulness and ... stimulant called orexin/hypocretin in the brain. Reduced activity in ...
... the first time, researchers have identified two important ... involved in degrading persistent pollutants such as PCBs. ... of Centre INRSInstitut Armand-Frappier in conjunction with U.S. ... help develop effective biocatalysts for resolving environmental pollution ...
... In an irony of nature, invasive species can become ... according to a recent discovery that could change how ... Princeton University researchers report this month in the ... evidence that destructive, non-native animals that have been deservedly ...
Cached Biology News:3 p.m. slump? Why a sugar rush may not be the answer 2Harm not those strangers that pollinate, study warns 2Harm not those strangers that pollinate, study warns 3Harm not those strangers that pollinate, study warns 4
... PAL label printer is portable, easy-to-use and makes ... Portable/Handheld Easy to use ... vial and slide sizes Time/Date stamp ... needs one Serialization feature makes you ...
... SPA Screening Assay, 5 x ... eliminate lengthy sample extraction procedures and ... 1.32-84.28 ng/ml (4-256 pmol/ml).Sensitivity: 0.65 ng/ml ... C. Category: Drug Screening & Cellular ...
The E. coli Expression System with Gateway Technology is designed to create E. coli expression clones containing the T7 promoter. The expression clones are ready for transformation and expression in ...
... C-1-tetrahydrofolate synthase, cytoplasmic ... Methylenetetrahydrofolate dehydrogenase (EC ... (EC; Formyltetrahydrofolate ... [Source:Uniprot/SWISSPROT;Acc:P11586] ...
Biology Products: